drugset / Trial / NCT00750425

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

NCT00750425

Phase 1 Completed 46 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.

Timeline

Start
2008-08
Primary completion
2009-04
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule 20 mg Oral
Subject Cediranib Small molecule 30 mg Oral
Subject Cediranib Small molecule 45 mg Oral
Subject Ketoconazole Small molecule 400 mg

Indications